Sandy Spring Bank Has $92,000 Stock Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Sandy Spring Bank raised its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 13.2% in the 4th quarter, HoldingsChannel reports. The fund owned 1,175 shares of the company’s stock after acquiring an additional 137 shares during the period. Sandy Spring Bank’s holdings in GE HealthCare Technologies were worth $92,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GEHC. Darwin Wealth Management LLC acquired a new position in GE HealthCare Technologies in the 3rd quarter valued at approximately $31,000. Continuum Advisory LLC increased its position in shares of GE HealthCare Technologies by 101.8% during the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after buying an additional 168 shares during the period. Bank of Jackson Hole Trust acquired a new stake in shares of GE HealthCare Technologies during the fourth quarter worth $32,000. OFI Invest Asset Management acquired a new stake in shares of GE HealthCare Technologies during the fourth quarter worth $34,000. Finally, Flagship Wealth Advisors LLC acquired a new stake in shares of GE HealthCare Technologies during the fourth quarter worth $34,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

GE HealthCare Technologies Stock Down 0.4 %

GE HealthCare Technologies stock opened at $81.49 on Friday. GE HealthCare Technologies Inc. has a 1-year low of $74.51 and a 1-year high of $94.80. The firm has a market capitalization of $37.27 billion, a price-to-earnings ratio of 18.82, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13. The firm’s fifty day moving average price is $87.02 and its two-hundred day moving average price is $86.02. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The firm had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. On average, equities research analysts predict that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GEHC. The Goldman Sachs Group upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $85.00 to $100.00 in a research report on Tuesday, March 11th. Citigroup increased their price objective on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Wells Fargo & Company raised their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price target for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, GE HealthCare Technologies has an average rating of “Moderate Buy” and an average target price of $98.75.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.